Nocdurna (Desmopressin)

Desmopressin, the active ingredient in Nocdurna, is a vasopressin analog presented as a sublingual formulation for sublingual use. It treats central diabetes insipidus, nocturnal enuresis, and primary nocturnal polyuria in appropriate patients.

GNH USA supplies Nocdurna as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Desmopressin acts on the antidiuretic pathway to reduce excessive urine output in several disorders.

Central diabetes insipidus: reduces polyuria by increasing renal water reabsorption. Nocturnal enuresis: decreases nighttime bedwetting episodes by concentrating urine. Primary nocturnal polyuria: lowers nocturnal urine volume, improving sleep continuity.

Desmopressin may cause a range of adverse reactions, from mild to severe.

Common Side Effects: - Headache - Nausea - Abdominal discomfort - Facial flushing - Mild hyponatremia - Dry mouth

Serious or Rare Side Effects: - Severe hyponatremia leading to seizures or coma - Water intoxication with cerebral edema - Allergic reactions such as rash or angioedema - Rare thrombotic events

Before prescribing Nocdurna, clinicians should consider several safety aspects.

Renal function: assess kidney status prior to initiation. Electrolytes: monitor serum sodium regularly during therapy. Fluid intake: advise patients to avoid excessive water consumption. Concomitant drugs: avoid simultaneous use with other antidiuretic agents. Pregnancy and lactation: use only if potential benefits outweigh risks. Store at ambient temperature: keep below 25 °C, retain original packaging, protect from moisture.

Desmopressin can interact with other medicines, requiring careful management.

Major Interactions (Avoid): - Concomitant use with other vasopressin analogues or antidiuretic drugs: risk of severe hyponatremia. - NSAIDs (e.g., ibuprofen, naproxen): may potentiate antidiuretic effect and increase hyponatremia risk. - Selective serotonin reuptake inhibitors (SSRIs): can enhance water retention leading to hyponatremia.

Moderate Interactions (Monitor Closely): - Diuretics, especially thiazides: may alter sodium balance, requiring monitoring. - CYP450 inhibitors (e.g., erythromycin): may affect metabolism of co‑administered drugs, monitor levels. - Anticoagulants (e.g., warfarin): rare reports of altered bleeding risk, monitor coagulation parameters.